Measurement of total body potassium with a shadow shield whole-body counter: calibration and errors

1. The use of a whole body counter in total body potassium estimations is described. The accuracy and value of the counter in measuring serial changes in total body potassium was assessed. 2. Serial study of twelve normal subjects at varying intervals revealed a normal variability in total body potassium of up to 1·23% (4-weekly measurements over 3 months). The error involved in counting statistics alone was 4%. 3. The whole body counter appears to be an accurate and useful method of assessing total body potassium in clinical studies.

Download Full-text

Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia

Blood ◽

10.1182/blood.v53.4.594.bloodjournal534594 ◽

1979 ◽

Vol 53 (4) ◽

pp. 594-603

Author(s):

P Chandra ◽

A Sawitsky ◽

AD Chanana ◽

G Chikkappa ◽

SH Cohn ◽

...

Keyword(s):

Chronic Lymphocytic Leukemia ◽

Cell Mass ◽

Leukemic Cell ◽

Lymphocytic Leukemia ◽

Clinical Staging ◽

Whole Body ◽

Total Body Potassium ◽

Body Counter ◽

Whole Body Counter ◽

Total Body

Total body leukemic mass in patients with chronic lymphocytic leukemia (CLL) was measured by quantitation of total body potassium (TBK) with a whole-body counter. In addition, the predicted normal total body potassium (Kp) for each patient was calculated from an empirically derived relationship involving height, weight, age, and sex. Both the absolute TBK and the relative excess of total body potassium (TBK/Kp) were related to the stage of disease. Patients in the early stages of CLL were found to have lower TBK and TBK Kp than patients in the late stages of disease. Both of these parameters increased with the successively advanced stages of the disease. The clinically monitored reduction of leukemic cell mass following therapy was accompanied by reductions in TBK and TBK/Kp. Data presented support the notion that TBK/Kp is a useful indicator of the total body leukemic mass. Furthermore, the results of these studies quantitatively validate the proposed clinical staging system for CLL. Quantitation of TBK by a whole-body counter is an accurate and noninvasive procedure and does not require administration of isotopes.

Download Full-text

Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia

Blood ◽

10.1182/blood.v53.4.594.594 ◽

1979 ◽

Vol 53 (4) ◽

pp. 594-603 ◽

Cited By ~ 16

Author(s):

P Chandra ◽

A Sawitsky ◽

AD Chanana ◽

G Chikkappa ◽

SH Cohn ◽

...

Keyword(s):

Chronic Lymphocytic Leukemia ◽

Cell Mass ◽

Leukemic Cell ◽

Lymphocytic Leukemia ◽

Clinical Staging ◽

Whole Body ◽

Total Body Potassium ◽

Body Counter ◽

Whole Body Counter ◽

Total Body

Abstract Total body leukemic mass in patients with chronic lymphocytic leukemia (CLL) was measured by quantitation of total body potassium (TBK) with a whole-body counter. In addition, the predicted normal total body potassium (Kp) for each patient was calculated from an empirically derived relationship involving height, weight, age, and sex. Both the absolute TBK and the relative excess of total body potassium (TBK/Kp) were related to the stage of disease. Patients in the early stages of CLL were found to have lower TBK and TBK Kp than patients in the late stages of disease. Both of these parameters increased with the successively advanced stages of the disease. The clinically monitored reduction of leukemic cell mass following therapy was accompanied by reductions in TBK and TBK/Kp. Data presented support the notion that TBK/Kp is a useful indicator of the total body leukemic mass. Furthermore, the results of these studies quantitatively validate the proposed clinical staging system for CLL. Quantitation of TBK by a whole-body counter is an accurate and noninvasive procedure and does not require administration of isotopes.

Download Full-text